Compugen Ltd.

As of May 22, 2025, the trend is mildly bearish, with daily moving averages indicating bearishness, weekly indicators showing mild bullishness, and monthly indicators leaning bearish.

As of March 2022, the management team of Compugen Ltd. includes Mr. Paul Sekhri (Chairman), Dr. Anat Cohen-Dayag (CEO), and several directors: Dr. Jean-Pierre Bizzari, Mr. Gilead Halevy, Dr. Kinneret Livnat Savitsky, Mr. Eran Perry, and Dr. Michal Preminger. They oversee the company's strategic direction and operations.

Compugen Ltd. is a therapeutic discovery company focused on drug target discovery and developing therapeutics, with a market cap of $154.30 million and recent net sales of $2 million. As of March 2025, it reported a net profit loss of $7 million.

As of Jun 18, Compugen Ltd. has a market capitalization of 154.30 million, with net sales of 27.58 million and a net profit of -14.14 million over the last four quarters.